Anti-PTK7 Antibody-drug Conjugate SKB518

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of an antibody directed against human inactive tyrosine-protein kinase 7 (protein tyrosine kinase 7; PTK7) conjugated to a DNA topoisomerase I inhibitor, with potential antineoplastic activity. Upon administration of anti-PTK7 ADC SKB518, the anti-PTK7 antibody targets and binds to PTK7 expressed on tumor cells. Upon binding and internalization, the topoisomerase I inhibitor inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in DNA damage, cell cycle arrest and apoptosis in tumor cells overexpressing PTK7. In addition, this may cause a bystander effect, thereby further killing PTK7-expressing tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells with limited expression in normal tissues. It is an integral player in cancer cell stemness and tumor progression.

**Synonyms:** - ADC SKB518 - Anti-PTK7 ADC SKB518 - SKB 518 - SKB-518 - SKB518